DK2753352T4 - Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf - Google Patents
Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf Download PDFInfo
- Publication number
- DK2753352T4 DK2753352T4 DK11769799.5T DK11769799T DK2753352T4 DK 2753352 T4 DK2753352 T4 DK 2753352T4 DK 11769799 T DK11769799 T DK 11769799T DK 2753352 T4 DK2753352 T4 DK 2753352T4
- Authority
- DK
- Denmark
- Prior art keywords
- toxin
- difficile
- proteins
- isolated polypeptide
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37989210P | 2010-09-03 | 2010-09-03 | |
| PCT/EP2011/065304 WO2012028741A1 (en) | 2010-09-03 | 2011-09-05 | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK2753352T3 DK2753352T3 (da) | 2017-03-06 |
| DK2753352T5 DK2753352T5 (da) | 2017-05-01 |
| DK2753352T4 true DK2753352T4 (da) | 2022-09-12 |
Family
ID=44799993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11769799.5T DK2753352T4 (da) | 2010-09-03 | 2011-09-05 | Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US9598472B2 (da) |
| EP (3) | EP3167899B1 (da) |
| JP (1) | JP6121421B2 (da) |
| KR (1) | KR101907434B1 (da) |
| CN (1) | CN103957931B (da) |
| AU (1) | AU2011298306B2 (da) |
| BR (1) | BR112014004896B1 (da) |
| CA (1) | CA2873272C (da) |
| CY (1) | CY1118664T1 (da) |
| DK (1) | DK2753352T4 (da) |
| ES (2) | ES2867375T3 (da) |
| HK (1) | HK1200357A1 (da) |
| HR (1) | HRP20170193T4 (da) |
| HU (1) | HUE033342T2 (da) |
| LT (1) | LT2753352T (da) |
| MX (1) | MX350126B (da) |
| PL (1) | PL2753352T5 (da) |
| PT (1) | PT2753352T (da) |
| RS (1) | RS55707B2 (da) |
| SI (1) | SI2753352T2 (da) |
| WO (1) | WO2012028741A1 (da) |
| ZA (1) | ZA201400610B (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350126B (es) | 2010-09-03 | 2017-08-28 | Valneva Austria Gmbh | Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo. |
| WO2012143902A1 (en) | 2011-04-22 | 2012-10-26 | Wyeth Llc | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
| AU2016203241B2 (en) * | 2011-05-27 | 2018-05-10 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| CN103717742B (zh) | 2011-05-27 | 2018-05-22 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| JP6084631B2 (ja) | 2011-12-08 | 2017-02-22 | ノバルティス アーゲー | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| US9694064B2 (en) * | 2012-12-05 | 2017-07-04 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB2525177A (en) * | 2014-04-14 | 2015-10-21 | New Royal Holloway & Bedford | Vaccine |
| US10533036B2 (en) * | 2015-02-19 | 2020-01-14 | Immune Biosolutions Inc | Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof |
| WO2017165398A1 (en) * | 2016-03-21 | 2017-09-28 | Children's Medical Center Corporation | Compositions and methods for inhibiting wnt signaling |
| MX2020013623A (es) | 2018-06-19 | 2021-03-25 | Glaxosmithkline Biologicals Sa | Composicion inmunogenica. |
| EP3931217A1 (en) * | 2019-02-25 | 2022-01-05 | PreviPharma Consulting GmbH | Epitopes of clostridium difficile toxins a and b and uses thereof |
| EP4133097A1 (en) | 2020-04-09 | 2023-02-15 | Valneva Austria GmbH | Improved methods of producing a lipidated protein |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5736139A (en) | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| US5547871A (en) | 1993-01-25 | 1996-08-20 | American Cyanamid Company | Heterologous signal sequences for secretion of insect controlling proteins |
| US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| EP1041149B8 (en) * | 1994-10-24 | 2007-10-03 | Allergan, Inc. | Vaccine and antitoxin for treatment and prevention of C. difficile disease |
| US5919463A (en) | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| WO1997002836A1 (en) | 1995-07-07 | 1997-01-30 | Oravax, Inc. | Clostridium difficile toxins as mucosal adjuvants |
| AU743412B2 (en) | 1996-10-04 | 2002-01-24 | Neuren Pharmaceuticals Limited | Regulation of neural enzymes |
| CA2276312C (en) | 1996-12-31 | 2012-11-27 | Jonathan A. Eppstein | Microporation of tissue for delivery of bioactive agents |
| US6733760B1 (en) | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| JP2002542169A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| PT1296713E (pt) | 2000-06-08 | 2004-02-27 | Intercell Biomediz Forschungs | Oligodesoxinucleotidos imunoestimuladores |
| US20040170642A1 (en) | 2000-08-17 | 2004-09-02 | Jorg Fritiz | Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| EP1390494A2 (en) | 2001-05-21 | 2004-02-25 | Intercell AG | Method for stabilising of nucleic acids |
| CA2452909A1 (en) | 2001-12-07 | 2003-06-13 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| KR101332927B1 (ko) * | 2004-02-06 | 2013-11-26 | 메다렉스, 인코포레이티드 | 클로스트리듐 디피실리 독소에 대한 항체 및 이의 용도 |
| JP4559431B2 (ja) | 2004-08-23 | 2010-10-06 | テバ ファーマシューティカル インダストリーズ リミティド | 固体及び結晶イバンドロネートナトリウム及びその調製方法 |
| CN101500581B (zh) * | 2006-06-08 | 2013-10-30 | 科内尔研究基金会 | 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法 |
| EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| EP2167119B1 (en) * | 2007-06-14 | 2016-08-24 | The Secretary of State for Health | Chemically modified peptides with improved immunogenicity |
| JP5503543B2 (ja) | 2007-09-14 | 2014-05-28 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
| WO2010017383A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| WO2011060431A2 (en) | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| KR101820987B1 (ko) | 2010-04-15 | 2018-01-22 | 프로제닉스 파머슈티컬스, 인코포레이티드 | 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체 |
| MX350126B (es) | 2010-09-03 | 2017-08-28 | Valneva Austria Gmbh | Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo. |
| WO2012143902A1 (en) * | 2011-04-22 | 2012-10-26 | Wyeth Llc | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
| CN103717742B (zh) | 2011-05-27 | 2018-05-22 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| GB201206070D0 (en) * | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| US9694064B2 (en) * | 2012-12-05 | 2017-07-04 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| GB201223342D0 (en) | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| US9181632B1 (en) * | 2013-09-09 | 2015-11-10 | Merck Sharp & Dohme Corp. | C.difficile toxin B CROP domain peptides, antibodies and complexes thereof |
-
2011
- 2011-09-05 MX MX2014002595A patent/MX350126B/es active IP Right Grant
- 2011-09-05 PL PL11769799.5T patent/PL2753352T5/pl unknown
- 2011-09-05 DK DK11769799.5T patent/DK2753352T4/da active
- 2011-09-05 EP EP16204515.7A patent/EP3167899B1/en active Active
- 2011-09-05 CN CN201180073256.XA patent/CN103957931B/zh active Active
- 2011-09-05 PT PT117697995T patent/PT2753352T/pt unknown
- 2011-09-05 ES ES16204515T patent/ES2867375T3/es active Active
- 2011-09-05 KR KR1020147005813A patent/KR101907434B1/ko active IP Right Grant
- 2011-09-05 AU AU2011298306A patent/AU2011298306B2/en active Active
- 2011-09-05 EP EP11769799.5A patent/EP2753352B2/en active Active
- 2011-09-05 HU HUE11769799A patent/HUE033342T2/en unknown
- 2011-09-05 JP JP2014527505A patent/JP6121421B2/ja active Active
- 2011-09-05 RS RS20170202A patent/RS55707B2/sr unknown
- 2011-09-05 SI SI201131113T patent/SI2753352T2/sl unknown
- 2011-09-05 ES ES11769799T patent/ES2631032T5/es active Active
- 2011-09-05 CA CA2873272A patent/CA2873272C/en active Active
- 2011-09-05 HR HRP20170193TT patent/HRP20170193T4/hr unknown
- 2011-09-05 WO PCT/EP2011/065304 patent/WO2012028741A1/en active Application Filing
- 2011-09-05 LT LTEP11769799.5T patent/LT2753352T/lt unknown
- 2011-09-05 US US14/342,565 patent/US9598472B2/en active Active
- 2011-09-05 BR BR112014004896-7A patent/BR112014004896B1/pt active IP Right Grant
- 2011-09-05 EP EP21157982.6A patent/EP3895728A1/en active Pending
-
2014
- 2014-01-24 ZA ZA2014/00610A patent/ZA201400610B/en unknown
-
2015
- 2015-01-30 HK HK15101036.7A patent/HK1200357A1/xx unknown
-
2017
- 2017-02-01 US US15/421,808 patent/US10357557B2/en active Active
- 2017-02-24 CY CY20171100260T patent/CY1118664T1/el unknown
-
2019
- 2019-03-07 US US16/295,031 patent/US10821166B2/en active Active
-
2020
- 2020-10-02 US US17/061,891 patent/US11357844B2/en active Active
-
2021
- 2021-08-19 US US17/406,765 patent/US11478540B2/en active Active
-
2022
- 2022-09-09 US US17/930,742 patent/US20230173052A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2753352T4 (da) | Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf | |
| LTPA2019012I1 (lt) | Plazmos kalikreiną surišantys baltymai | |
| DK3168229T3 (da) | Fremstilling af proteiner og polypeptider. | |
| DK3130347T3 (da) | PH20-polypeptidvarianter, formuleringer og anvendelser deraf | |
| DK2542590T4 (da) | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner | |
| CO7020851A2 (es) | Proteínas y péptidos modificados | |
| DK2638173T3 (da) | Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf | |
| DK2728002T3 (da) | Heterodimeriseret polypeptid | |
| DK3662932T3 (da) | Anti-cgrp-sammensætninger og anvendelse deraf | |
| EP2709603A4 (en) | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS AND APPLICATIONS THEREWITH | |
| DK3321287T3 (da) | Fusionsproteiner og kombinationsvacciner | |
| DK2624866T3 (da) | Tumorspecifikke antistoffer og anvendelser deraf | |
| DK3572091T3 (da) | Modificerede relaxinpolypeptider og anvendelser deraf | |
| DK2552434T3 (da) | Peptider og anvendelse deraf | |
| DK2538666T3 (da) | Fjernstyringsterminal og informationsbehandlingsapparat | |
| DK3498292T3 (da) | Uspa2-proteinkonstruktioner og anvendelser deraf | |
| DK2729160T3 (da) | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet | |
| DK2555789T3 (da) | Hæmmende peptider afledt af trem-lignende transcript 1 (tlt-1) og anvendelser deraf | |
| DK3085777T3 (da) | Polypeptid | |
| DK2545168T3 (da) | Modificerede cellulaser fra familie 5 og anvendelser deraf | |
| DK3010535T3 (da) | Toxoide peptider afledt fra fenol opløselige modulin, delta toxin, superantigener og fusioner deraf | |
| DK3173102T3 (da) | FGFR-FC-fusionsprotein og anvendelse deraf | |
| DK2855676T3 (da) | SAMMENSÆTNINGER OG FREMGANGSMÅDER TIL PEPTIDEKSPRESSION OG -OPRENSNING UNDER ANVENDELSE AF ET TYPE lll-SEKRETIONSSYSTEM | |
| EP2747773A4 (en) | METHODS AND COMPOSITIONS COMPRISING A PEPTIDE DERIVED FROM THE B-TERMINAL END OF BAX | |
| DK3346273T3 (da) | Hidtil ukendte d-enantiomer peptider afledt af d3 og anvendelse deraf |